The MiSeq i100 Plus is Illumina’s newest benchtop sequencer — from the world’s leading brand in NGS technology. More than a conventional sequencing instrument, the MiSeq i100 Plus represents a significant leap forward in performance, speed, and accuracy, meeting the ever-growing demands of clinical and research laboratories.
Eurofins GENTIS’s pioneering adoption of this system clearly reflects its strategic, long-term investment vision to deliver the most advanced genetic testing solutions to the community.
One of the most outstanding advantages of the MiSeq i100 Plus is its exceptional sequencing speed. By leveraging advanced chemistry and an optimized workflow, the system significantly shortens run times, enabling many NGS-based tests to deliver same-day results while maintaining high accuracy and data reliability.
This capability is particularly critical in clinical settings requiring rapid decision-making, allowing physicians to implement timely and effective treatment strategies.
In addition to speed, the MiSeq i100 Plus features a “Touch & Run” plug-and-play design, simplifying complex technical procedures. The integrated reagent cartridge minimizes manual preparation steps, thereby reducing human error and enhancing consistency between runs. With its user-friendly design and high level of automation, Eurofins GENTIS’s technical team can operate the system smoothly and reliably, while dedicating greater focus to in-depth analysis and rigorous quality control.
The system incorporates Illumina’s proprietary XLEAP-SBS™ technology, delivering superior read quality and significantly improving the accuracy and reliability of sequencing data. This allows the platform to precisely detect and analyze complex genetic variants, meeting the stringent requirements of modern genetic testing across both clinical and research applications.
With installation, technology transfer, and continuous technical support from Mitalab, Eurofins GENTIS is maximizing the capabilities of the MiSeq i100 Plus across multiple critical fields of medicine and molecular biology.
NGS enables accurate analysis of chromosomal abnormalities and pathogenic genetic variants, significantly enhancing reproductive health counseling and care, and helping many families realize their dream of parenthood.
The MiSeq i100 Plus plays a pivotal role in early detection of cancer-related genetic mutations, comprehensive tumor genomic profiling, and the development of targeted treatment regimens.
This forms the foundation of precision medicine, where each patient receives therapies tailored to their unique genetic profile — improving treatment outcomes and quality of life.
The system expands capabilities in diagnosing rare diseases and conducting high-sensitivity microbial studies, enabling the detection of novel or hard-to-identify pathogens beyond the limits of conventional methods.
These advancements contribute not only to clinical effectiveness but also to biomedical research and healthcare development in Vietnam.
Becoming the first organization in Vietnam to deploy the MiSeq i100 Plus once again reinforces Eurofins GENTIS’s leadership position in genetic testing and diagnostics.
This milestone reflects not only technological achievement but also the company’s strategic vision, deep professional expertise, and long-term commitment to bringing the world’s most advanced medical technologies closer to the Vietnamese community.
Looking ahead, Eurofins GENTIS will continue making strong investments in technological infrastructure, human resources, and international collaboration — partnering with the healthcare sector to elevate diagnostic quality, advance personalized medicine, and safeguard public health.
